# Safety and Effectiveness of Cinnomer® (Glatiramer Acetate) in Multiple Sclerosis (MS) Treatment in Iran

> **NCT04928313** · — · COMPLETED · sponsor: **Cinnagen** · enrollment: 368 (actual)

## Conditions studied

- Relapsing Multiple Sclerosis

## Interventions

- **DRUG:** Glatiramer Acetate

## Key facts

- **NCT ID:** NCT04928313
- **Lead sponsor:** Cinnagen
- **Sponsor class:** INDUSTRY
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** COMPLETED
- **Start date:** 2015-04-12
- **Primary completion:** 2020-02-17
- **Final completion:** 2020-02-17
- **Target enrollment:** 368 (ACTUAL)
- **Last updated:** 2021-06-16


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04928313

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04928313, "Safety and Effectiveness of Cinnomer® (Glatiramer Acetate) in Multiple Sclerosis (MS) Treatment in Iran". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT04928313. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*